All In Biotech

NDA 207932 · Bdsi

Belbuca

Buprenorphine Hydrochloride · Buccal

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 23, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

512

125 Phase 3, 43 recruiting

FAERS reports

7,463

5,578 serious, 1,051 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA WARNING: SERIOUS LIFE-THREATENING RISKS FROM USE OF BELBUCA See full prescribing information for complete boxed warning. BELBUCA exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.1 ) Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Instruct patients on proper administration of BELBUCA to reduce the risk. ( 2.1 , 2.8 , 5.2 ) Accidental exposure to BELBUCA, especially in children, can result in fatal overdose of buprenorphine. ( 5.2 ) Concomitant use of opioids with benzodiazepines or other central...

What it is approved for

From the label in effect Jan 2, 2026.

BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. BELBUCA buccal film contains buprenorphine, a partial opioid agonist. BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including BELBUCA, for use in patients for whom alternative treatment are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) BELBUCA is not indicated as an as-needed (prn) analgesic. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including BELBUCA, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. BELBUCA is not indicated as an as-needed (prn) analgesic.

Mechanism: Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • BELBUCA · BUPRENORPHINE HYDROCHLORIDE EQ 0.3MG BASE · FILM, BUCCAL · Prescription
  • BELBUCA · BUPRENORPHINE HYDROCHLORIDE EQ 0.075MG BASE · FILM, BUCCAL · Prescription
  • BELBUCA · BUPRENORPHINE HYDROCHLORIDE EQ 0.75MG BASE · FILM, BUCCAL · Prescription
  • BELBUCA · BUPRENORPHINE HYDROCHLORIDE EQ 0.45MG BASE · FILM, BUCCAL · Prescription
  • BELBUCA · BUPRENORPHINE HYDROCHLORIDE EQ 0.15MG BASE · FILM, BUCCAL · Prescription
  • BELBUCA · BUPRENORPHINE HYDROCHLORIDE EQ 0.9MG BASE · FILM, BUCCAL · Prescription
  • BELBUCA · BUPRENORPHINE HYDROCHLORIDE EQ 0.6MG BASE · FILM, BUCCAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Buprenorphine" as an intervention, any sponsor and status, largest first.

All 512 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dependence2,858
  • overdose1,452
  • death461
  • drug ineffective426
  • ill-defined disorder414
  • nausea352
  • pain330
  • headache309
  • foetal exposure during pregnancy306
  • depression292
  • product adhesion issue276
  • maternal exposure during pregnancy273

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200476
200514
200619
20074
200833
200921
201032
201125
201226
2013155
201445
201569
2016289
2017138
2018155
2019222
2020264
2021199
2022532
20233,285
2024837
2025711
2026311

Recalls

2 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Belbuca (Buprenorphine HCl)

2024 spending

$160M

Beneficiaries

38,169

217,647 claims

Per beneficiary

$4,195

$12.76 per unit

View as table
YearSpending
2020$104,294,677
2021$121,461,132
2022$136,081,121
2023$149,974,661
2024$160,135,997

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,775 on PubMed

Sponsor: Bdsi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.